|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | * 1. **years**   **% (95% CI)** | **1-6 years**  **% (95% CI)** | **6-18 years**  **% (95% CI)** | **P-value\*** |
| ***S. pneumonia*** |  |  |  |  |
| All isolates, n  *Resistance rates,* *% (95% CI)* | 40 | 73 | 38 |  |
| Penicillin NS | 5.0 (0.6-16.9) | 13.7 (6.8-23.8) | 15.8 (6.0-31.3) | 0.252 |
| Erythromycin | 7.5 (1.6-20.4) | 11.0 (4.9-20.5) | 15.8 (6.0-31.3) | 0.530 |
| Clindamycin | 7.5 (1.6-20.4) | 8.2 (3.1-17.0) | 13.2 (4.4-28.1) | 0.670 |
| SXT | 7.5 (1.6-20.4) | 24.7 (15.3-36.1) | 15.8 (6.0-31.3) | 0.070 |
| Multi-resistance# | 2.5 (0.06-13.2) | 9.6 (3.9-18.8) | 7.9 (1.7-21.4) | 0.685 |
| ***S. aureus*** |  |  |  |  |
| All isolates, n  *Resistance rates, % (95% CI)* | 119 | 45 | 165 |  |
| Beta-lactamase | 79.0 (70.1-85.9) | 73.3 (58.1-85.4) | 68.3 (60.6-75.3) | 0.135 |
| Erythromycin | 7.6 (3.5-13.9) | 2.2 (0.06-11.8) | 3.1 (1.0-7.0) | 0.167 |
| Ciprofloxacin | 0.8 (0.2-4.6) | 4.4 (0.5-15.1) | 1.8 (0.4-5.3) | 0.237 |
| ***E. coli*** |  |  |  |  |
| All isolates, n | 131 | 28 | 53 |  |
| *Resistance rates, % (95% CI)* |  |  |  |  |
| Gentamicin | 3.8 (1.3-8.7) | 7.1 (0.9-23.5) | 11.3 (4.3-23.0) | 0.121 |
| Ampicillin | 42.0 (33.4-50.9) | 39.3 (21.5-59.4) | 56.6 (42.3-70.2) | 0.155 |
| Ciprofloxacin | 6.1 (2.7-11.7) | 7.1 (0.9-23.5) | 11.3 (4.3-23.0) | 0.442 |
| SXT | 19.6 (13.4-27.8) | 28.6 (13.2-48.7) | 43.4 (29.8-57.7) | ***0.005*** |
| ESBL | 2.3 (0.5-6.5) | 7.1 (0.9-23.5) | 0.0 (0.0-6.7) | 0.120 |

**Supplemental Digital Content 4.** Comparison of resistance rates for selected bacteria between different age-groups in Norwegian children, 2013-2017.

Penicillin NS; penicillin nonsusceptibility; SXT; trimethoprim/sulfamethoxazole

\* Chi squared test comparing the proportion of resistant isolates. Fisher`s exact test was used if any expected frequency <5.

# Resistant (or non-susceptible to penicillin) to three or more of the antibiotics above